Sasaki Motoko, Sato Yasunori, Nakanuma Yasuni
Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Pathol Res Pract. 2025 Jun;270:155999. doi: 10.1016/j.prp.2025.155999. Epub 2025 May 8.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) shares various features with small duct type intrahepatic cholangiocarcinoma (SmD-iCCA) and sometimes histological diagnosis may be difficult.
We examined genetic alterations such as hTERT promoter (hTERT), p53, and fibroblast growth factor receptor 2 (FGFR2) in 103 PLCs diagnosed as cHCC-CCA or SmD-iCCA. A cluster analysis was performed on the R software for re-classification of PLCs including cHCC-CCA and SmD-iCCA.
The primary liver carcinomas (PLCs) were divided into 5 clusters; 19 tumors (18 %) in Cluster-1 (with alterations in hTERT and/or p53), 24 (23 %) in Cluster-2 (FGFR2 and/or p53), 13 (13 %) in Cluster-3 (IDH2 or null), 19 (18 %) in Cluster-4 (MTAP and/or FGFR2), 28 (27 %) in Cluster-5 (ARID1A and/or PBRM1), being based on genetic alterations. Cluster-1 and Clusters-2 to- 5 formed distinct 2 groups. Cluster-1 was characterized by significantly bigger size, rich and higher histological grade of HCC component, significantly less cholangiolocellular carcinoma (CLC)-component, ductal plate malformation pattern and bile duct adenoma in the background livers. No SmD-iCCA was included in Cluster-1, whereas SmD-iCCA distributed evenly in Clusters 2-5. Cluster-4 was characterized by higher prevalence of hepatitis B and higher histological diversity scores.
PLCs diagnosed as cHCC-CCA or SmD-iCCAs could be divided into 5 clusters based on genetic alterations. Cluster-1 was HCC-like cluster characterized by hTERT alteration, rich and higher grade of HCC and bigger size. Clusters-2-5 may be iCCA-like clusters characterized by different genetic alterations. cHCC-CCA in Cluster-1 and Clusters-2-5 may be handled separately for further analysis and treatment.
肝细胞-胆管细胞癌(cHCC-CCA)与小胆管型肝内胆管癌(SmD-iCCA)具有多种共同特征,有时组织学诊断可能较为困难。
我们检测了103例诊断为cHCC-CCA或SmD-iCCA的原发性肝癌(PLC)中的hTERT启动子(hTERT)、p53和成纤维细胞生长因子受体2(FGFR2)等基因改变。在R软件上进行聚类分析,对包括cHCC-CCA和SmD-iCCA在内的PLC进行重新分类。
原发性肝癌(PLC)被分为5个簇;第1簇中有19个肿瘤(18%)(hTERT和/或p53有改变),第2簇中有24个(23%)(FGFR2和/或p53),第3簇中有13个(13%)(异柠檬酸脱氢酶2(IDH2)改变或无改变),第4簇中有19个(18%)(甲基硫代腺苷磷酸核糖转移酶(MTAP)和/或FGFR2),第5簇中有28个(27%)(AT丰富相互作用域1A(ARID1A)和/或溴结构域包含蛋白7(PBRM1)),分类基于基因改变。第1簇与第2至5簇形成了明显的两组。第1簇的特征是肿瘤体积显著更大,HCC成分丰富且组织学分级更高,胆管细胞癌(CLC)成分显著更少,背景肝脏中的胆管板畸形模式和胆管腺瘤更少。第1簇中不包括SmD-iCCA,而SmD-iCCA在第2至5簇中分布均匀。第4簇的特征是乙肝患病率更高且组织学多样性评分更高。
诊断为cHCC-CCA或SmD-iCCA 的PLC可根据基因改变分为5个簇。第1簇是类似HCC的簇,其特征为hTERT改变、HCC丰富且分级高以及体积大。第2至5簇可能是类似iCCA的簇,其特征为不同的基因改变。第1簇和第2至5簇中的cHCC-CCA在进一步分析和治疗时可能需要分别处理。